Randomized clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation



Agonists of 5-hydroxytryptamine 4 receptors are potential agents for irritable bowel syndrome with predominant constipation (IBS-C). However, only tegaserod has been approved for a very limited population in the US. The aim of the study was to evaluate the efficacy and safety of minesapride in patients with IBS-C.

A greater percentage of minesapride 40 mg-treated patients than placebo-treated patients met both responder requirements for ≥9/12 weeks and the stricter composite evaluation (P < 0.05). Furthermore, minesapride 40 mg significantly increased SBM frequency compared with placebo (adjusted P < 0.001 at Week 12). The most common adverse event was mild diarrhea.

Conclusions: Minesapride was safe and well-tolerated in patients with IBS. Although the primary endpoint was negative, minesapride 40 mg is likely to improve the stricter composite endpoint and SBM frequency.


Please enter your comment!
Please enter your name here